Primary Audience:

Oncologists and other health care professionals who treat and care for patients with breast cancer.

Learning Objectives

Upon completion of the activity, participants should be able to: 

1. Interpret results from new and existing HER2 testing methodologies to determine appropriate treatment decisions 
2. Differentiate between the prognostic and predictive implications associated with HER2 positivity 
3. Compare and contrast monoclonal antibodies and tyrosine kinase inhibitors available for the treatment of HER2-positive breast cancer 
4. Apply evidence-based clinical trial data on new and emerging treatment strategies to ensure optimal care for patients with HER2-positive breast cancer 
5. Monitor and manage treatment-related toxicities associated with chemotherapeutic and biologic agents used to treat HER2-positive breast cancer

Faculty Disclosure Statement:

education | outcomes | science is a CME provider accredited by the ACCME. In compliance with the Standards for Commercial Support, it is our policy to require everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest occurring within the 12 months prior to an activity's release date. The staff of education | outcomes | science involved with this activity have reported no relevant financial relationships with commercial interests.

Hardware/Software Requirements:

PC – Internet Explorer (v6 or greater) or Firefox.
Mac – or Safari